Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

April 17-18, 2015

New York, New York


Scientific Agenda

Friday, April 17, 2015

8:00 am

Introduction and pre-activity audience survey

Session I: Plasma Cell Disorders

Session Chair: Robert Z. Orlowski, MD, PhD

8:10 am

Lecture: The future of antibody therapies and drug conjugates in multiple myeloma
Sagar Lonial, MD

8:40 am

Debate: Are two or three drugs a reasonable frontline regimen for newly diagnosed transplant ineligible myeloma?

Two drugs
Sagar Lonial, MD

Three drugs
Paul Richardson, MD

9:10 am

Debate: Which is optimal as induction therapy for newly diagnosed transplant eligible myeloma?

Triplet regimens
Paul Richardson, MD

Quadruplet regimens
Ruben Niesvizky, MD

9:40 am


9:55 am

Lecture: Emerging small molecule therapies with promise
Robert Z. Orlowski, MD, PhD

10:20 am

Challenging Cases in Multiple Myeloma Panel

11:05 am

Debate: Should consolidation therapy and minimal residual disease testing be used for monitoring and treatment?
Suzanne Lentzsch, MD, PhD

Sagar Lonial, MD

11:35 pm

Debate:What is optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction, ASCT and consolidation?
Maintenance for 2 years only
Suzanne Lentzsch, MD, PhD

Continuous maintenance therapy
Ruben Niesvizky, MD

12:05 pm

Final remarks and post-activity audience survey

12:15 pm


Session II: Chronic Lymphocytic Leukemia

Session Chair: David P. Steensma, MD

2:00 pm

Debate: What is the best frontline regimen for a CLL patient aged 60 who requires therapy?
Matthew S. Davids, MD, MMSc

Ibrutinib-based treatment without chemotherapy
Richard R. Furman, MD

2:30 pm

Lecture: New anti-CD20 antibodies for CLL – are they better than rituximab?
Bruce D. Cheson, MD

2:55 pm

Debate: What is the best approach for a patient with multiple relapsed CLL after chemoimmunotherapy
Allogeneic stem cell transplant
Koen Van Besien MD

Kinase inhibitor therapy
Bruce D. Cheson, MD

Other novel agents
Matthew S. Davids, MD, MMSc

3:40 pm


Session III: Chronic Myeloid Leukemia

Session Chair: David P. Steensma, MD

3:55 pm

Lecture: Management of thrombosis risk with ponatinib and other TKIs for CML?
Javid Moslehi, MD

4:20 pm

Lecture: How should chronic-phase CML management be influenced by RT-PCR results at 3 months and beyond?
Jeffrey H. Lipton, MD, PhD, FRCPC

4:45 pm

Lecture: Who should still be transplanted for CML in 2015?
Jerry P. Radich, MD

5:10 pm

Final remarks and post-activity audience survey

5:15 pm


Saturday, April 18, 2015

8:00 am

Welcome and pre-activity audience survey

Session IV: Not-So-Benign Hematology

Session Chair: David P. Steensma, MD

8:10 am

Lecture: Evaluation of minor prolongation of coagulation times
Ken A. Bauer, MD

8:35 am

Lecture: Treatment and prevention of heparin-induced thrombocytopenia
Lawrence Rich, MD

9:00 am

Lecture: Anticoagulation Management and Difficult Cases
Jean M. Connors, MD

Session V: Acute Leukemia

Session Chair: David P. Steensma, MD

9:25 am

Lecture: An overview of new therapies for ALL
Dan J. DeAngelo, MD, PhD

9:50 am


Session VI: MPNs and MDS

Session Chair: David P. Steensma, MD

10:05 am

Lecture: Management of lower-risk MDS without del5q and refractory to ESAs
Amy E. DeZern, MD, MHS

10:30 am

Lecture: IPSS, DIPSS, DIPSS-Plus, MISPS, GIPSS: making sense of the tangled web of prognostic scoring systems in MF
John Mascarenhas, MD

10:55 am

Debate: Should JAK2 inhibitors be used for lower-risk MF, or only on-label (higher-risk)?
Ruben A. Mesa, MD

More data is needed
John Mascarenhas, MD

11:25 am

Lecture: Management of MDS patients for whom a hypomethylating agent has failed
David Steensma, MD

11:50 am

Final remarks and post-activity audience survey

12:00 pm


Session VII: Lymphomas

Session Chair: John P. Leonard, MD

1:30 pm

Welcome and pre-activity audience survey

1:35 pm

Debate: A 48-year-old woman is diagnosed with mildly symptomatic, low tumor burden, stage IV follicular lymphoma, low risk FLIPI score and desires treatment. What would you recommend to her?
Peter Martin, MD

Single agent rituximab or a combination “biologic doublet” therapy
Bruce Cheson, MD

2:05 pm

Debate: A 60 year old man with stage I (excised) follicular lymphoma, now NED. How should he be treated?
Morton Coleman, MD

Radiation therapy, with or without systemic treatment
Jonathan Friedberg MD

2:35 pm

Lecture: Kinase inhibitors and immunomodulatory drugs – What does the future hold for lymphomas?
John P. Leonard, MD

3:00 pm


3:15 pm

Debate: How should a 63 year old male with advanced stage, low risk MIPI mantle cell be treated outside of a clinical trial?
Chemoimmunotherapy with AutoSCT -
Koen van Besien, MD, PhD

Chemotherapy-based therapy without transplant
John P. Leonard, MD

3:45 pm

Lecture: Double hit lymphoma. What is it and how should we treat it?
Jonathan Friedberg, MD

4:10 pm

Debate: Should we treat patients with DLBCL differently today based on cell of origin (Germinal Center/Non-Germinal Center)?
Richard I. Fisher, MD

Peter Martin, MD

4:40 pm

Lecture: Radiation in Hodgkin Lymphoma – Who should get it, who should not get it?
David Straus, MD

5:05 pm

Debate: What is the optimal management for a 65 year old patient with peripheral T cell lymphoma relapsed after upfront chemotherapy?
Stem cell transplantation (allo or auto)
Barbara Pro, MD

Sequential novel agents
Jia Ruan, MD, PhD

5:35 pm

Final remarks and post-activity audience survey

5:40 pm